PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Circulating GDF11 levels are decreased with age but are unchanged with obesity and type 2 diabetes

    Añón-Hidalgo J (1), Catalán V (1,2,3), Rodríguez A (1,2,3), Ramírez B (1,2,3), Silva C (2,3,4), Galofré JC (4), Salvador J (2,4), Frühbeck G (1,2,3,4), Gómez-Ambrosi J (1,2,3).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

    Aging 21 de MARÇO de 2019

  • Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Borrero-Palacios A (1), Cebrián A (2), Gómez Del Pulgar MT (1), García-Carbonero R (3), García P (4), Aranda E (5), Elez E (6), López-López R (7), Cervantes A (8), Valladares M (9), Nadal C (10), Viéitez JM (11), Guillén-Ponce C (12), Rodríguez J (13), Hernández I (14), García JL (15), Vega-Bravo R (16), Puime-Otin A (16), Martínez-Useros J (1), Del Puerto-Nevado L (1), Rincón R (1), Rodríguez-Remírez M (1), Rojo F (16), García-Foncillas J (17).

    (1) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (2) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (3) Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
    (4) Medical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain.
    (5) Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
    (6) Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
    (7) Medical Oncology Department, Complexo Hospitalario Universitario Santiago de Compostela, Galicia, Spain.
    (8) Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
    (9) Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain.
    (10) Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
    (11) Medical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain.
    (12) Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (13) Medical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain.
    (14) Medical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
    (15) Oncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany.
    (16) Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
    (17) Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.

    Scientific Reports 20 de FEVEREIRO de 2019

  • CT screening for lung cancer: comparison of three baseline screening protocols [ES]

    Henschke CI (1,2,3), Yip R (4), Ma T (4,5), Aguayo SM (6), Zulueta J (7), Yankelevitz DF (4); Writing Committee for the I-ELCAP Investigators.

    (1) Icahn School of Medicine at Mount Sinai, New York, NY, USA. Claudia.
    (2) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA. Claudia.
    (3) Department of Radiology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY, 10029, USA. Claudia.
    (4) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (5) Department of Diagnostic Ultrasound, Tong Ren Hospital, Capital Medical University, Beijing, 100730, China.
    (6) Phoenix Veterans Affairs Health Care System, Phoenix, AZ, USA.
    (7) Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Navarra, Spain.

    European Radiology 03 de DEZEMBRO de 2018

  • Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma

    Usmani SZ (1), Hoering A (2), Cavo M (3), Miguel JS (4), Goldschimdt H (5), Hajek R (6), Turesson I (7), Lahuerta JJ (8), Attal M (9), Barlogie B (10), Lee JH (11), Kumar S (12), Lenhoff S (13), Morgan G (14), Rajkumar SV (15), Durie BGM (16), Moreau P (17).

    (1) Hematogic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, United States.
    ()2 Cancer Research and Biostatistics, Seattle, Washington, United States.
    (3) Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
    (4) Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Clinica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
    (6) University Hospital Ostrava and the Faculty of Medicine, CRAB, University of Ostrava Adam Rosenthal, Seattle, United States.
    (7) Department of Hematology, Malmo University Hospital, Malmo, Sweden.
    (8) Hospital Universitario 12 de Octubre, Madrid, Spain.
    (9) Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
    (10) Hematology, Mount Sinai University, New York, United States.
    (11) Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea.
    (12) Department of Internal Medicine, Division of Hematology, Mayo clinic, Rochester, MN, United States.
    (13) Skane University Hospital, Lund, Sweden.
    (14) MIRT, UAMS, Myeloma Insitute, Little Rock, United States.
    (15) Division of Hematology, Mayo Clinic, Rochester, MN, United States.
    (16) Hematology/Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, United States.
    (17) Service d'Hematologie, CHU de Nantes, Nantes, France.

    Blood Cancer Journal 23 de NOVEMBRO de 2018

  • Comparison of correlations of equation-derived body fat percentage and body mass index with carotid intima-media thickness

    Landecho MF (1,2), Colina I (1,2), Sunsundegui P (1), Camarero B (3), Núñez-Córdoba JM (4,5), Beloqui Ó (1,2).

    (1) General Health Check-up Unit, Internal Medicine Department, Clínica Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (2) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
    (3) General Surgery and Digestive System Service, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (4) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
    (5) Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Avenida Pío XII, 36, 31008, Pamplona, Spain.

    Acta Diabetológica 23 de NOVEMBRO de 2018

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra